BioWa Announces Expansion of License Agreement with Genentech for BioWa's POTELLIGENT(R) Technology.
PR Newswire Europe, March, 2008
PRINCETON, New Jersey, March 3 /PRNewswire/ --
BioWa, Inc. announced today that it has expanded the license agreement with Genentech, Inc. providing Genentech additional access to BioWa's POTELLIGENT(R) Technology for the research and development of select antibodies for potential therapeutic applications that require enhancement of antibody-dependent cellular cytotoxicity (ADCC).
"BioWa is pleased to extend this license with Genentech, which is a market leader in the field of antibody therapeutics," commented Dr. Masamichi Koike, President and CEO of BioWa. "We feel this alliance will strongly aid in the development of more effective targeted treatments for cancer and other diseases."
Under the terms of the expanded license agreement,...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- LIFO vs. FIFO: a return to the basics
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- Design a commission plan that drives sales - Sales Commissions
